Oxycodone/naloxone (Targin®)

Assessment Status Assessment process complete
HTA ID -
Drug Oxycodone/naloxone
Brand Targin®
Indication For severe pain, which can be adequately managed only with opioid analgesics.
Assessment Process
Full pharmacoeconomic assessment commissioned by HSE 05/05/2010
NCPE assessment completed 12/07/2010

Technical Summary

13/07/2010
We do not recommend reimbursement of oxycodone/naloxone (Targin®) under the Community Drugs Schemes at the proposed price.

19/10/2010
Following a price revision oxycodone/naloxone (Targin®) is now reimbursed under the Community Drugs Schemes.